Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes

Background: Tigecycline is a therapeutic option for carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Our aim was to evaluate the impact of the tigecycline’s minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline monotherapy. Methods: P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antibiotics (Basel)
Main Authors: Papadimitriou-Olivgeris, Matthaios, Bartzavali, Christina, Nikolopoulou, Alexandra, Kolonitsiou, Fevronia, Mplani, Virginia, Spiliopoulou, Iris, Christofidou, Myrto, Fligou, Fotini, Marangos, Markos
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699267/
https://ncbi.nlm.nih.gov/pubmed/33228012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics9110828
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados